It’s time we ended the threat of infectious disease

Worldwide, infectious diseases kill over 17 million people annually. One in three patients who die in a hospital have sepsis. That’s why BOA has engineered a new standard of care that facilitates rapid diagnosis and unparalleled treatment of infection resulting in the removal of pathogens from the bloodstream, regardless of pathogen type.

Play video

Breakthrough technology makes it possible

Developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University, funded by $150 million in research by the U.S. Department of Defense and their research agency, DARPA, and licensed by BOA Biomedical in 2018; BOA’s technology reduces the need for new pathogen-specific diagnostics and therapeutics that have lengthy and costly development timelines. This pan-pathogen approach is an advancement for infectious disease management.

BOA’s engineered protein binds to a wide range of pathogens, including pseudo SARS-CoV-2 and other viruses, bacteria, fungi and parasites. This technology has several diagnostic and therapeutic applications.

BOA’s ecosystem of products reflects a deep understanding of the challenges facing those on the front lines of infectious disease.

Detect

Rapid detection

Recognize active infection and assess infection severity and sepsis within minutes in any setting, including the home.

expand close

Detect active infection and level of severity from a blood sample within 1 hour

Identifying serious infection can be difficult, even in the most advanced emergency rooms, and it can take days for doctors to get test results. What if you could know that you have an infection and how severe it is in minutes?

BOA’s rapid pan-pathogen detection system recognizes active infection caused by bacteria, fungi, viruses and parasites directly from a patient’s sample within minutes and has been initially verified in human clinical study. Fast detection is important in the treatment of sepsis, where mortality rates increase as much as 8% for every hour before correct therapy is administered.

This approach allows for point-of-care applications beyond the hospital setting which can empower patients with the freedom and peace of mind that comes with testing from home or in austere environments. This technology represents an important aspect of the Miraki Convergence Theorem^TM, the integration of which will create new opportunities for effective and affordable healthcare around the world.

Diagnose

Rapid pathogen identification

Accurately identify Infection-causing pathogens, within one hour, without the need for blood cultures.

expand close

Identify pathogens without the need for blood cultures within 1 hour

Is the cough you are suffering from a result of the common cold or a deadly virus? Today’s diagnostics can be imprecise or take days to run when every hour matters in the treatment of infectious disease.

At least 30 new diseases have emerged in the past 45 years which together now threaten the health of hundreds of millions of people around the world. Easily scalable to novel pathogens, BOA’s culture-free, rapid pan-pathogen identification system discovers active infection caused by pathogens including bacteria, fungi, viruses and parasites directly from a patient’s blood sample in less than one hour.

This is a breakthrough rapid, comprehensive, direct-from-patient sample, microbial identification system. The system has already had initial testing on human blood with pathogens and the results are promising.

When implemented, it provides real-time diagnostic guidance for the treatment of infections, in addition to sepsis and COVID-19 complications. This guidance is important in the treatment of sepsis, where mortality rates increase as much as 8% for every hour before correct therapy is administered, and more when drug-resistant pathogens are involved.

Treat

Pathogen toxin removal

Filter pathogens and pathogen by-products directly from a patient’s blood using an extracorporeal therapeutic filter.

expand close

Filter harmful toxins directly from a patient's blood

When patients become sick with an infection, their body is under attack. Not only is the pathogen making the patient sick, but for some patients the body’s immune response can make the problem even worse.

Many pathogens such as SARS-CoV-2 leave healthcare providers without proven treatment protocols. BOA’s therapeutic filter aims to directly remove pathogens and their toxic products from a patient’s bloodstream, regardless of the type of pathogen or level of antimicrobial resistance. This has the potential to considerably help the patient’s immune system win the fight. This treatment will enter human clinical trials in the near future.

Compassionate Use Policy